NCT02317991View on ClinicalTrials.gov

Study of Nab-Paclitaxel and Ramucirumab as Second-line Treatment for Patients With Metastatic Gastroesophageal Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

65

Participants

Timeline

Start Date

May 5, 2015

Primary Completion Date

May 21, 2021

Study Completion Date

May 21, 2021

Conditions
Gastroesophageal Cancer
Interventions
DRUG

nab-paclitaxel

nab-paclitaxel 125 mg/m\^2 IV

BIOLOGICAL

ramucirumab

Ramucirumab 8 mg/kg IV

Trial Locations (11)

29303

Spartanburg Medical Center/Gibbs Cancer Center, Spartanburg

32804

Florida Hospital Cancer Institute, Orlando

33705

Florida Cancer Specialists-North, St. Petersburg

33916

Florida Cancer Specialists-South, Fort Myers

37203

Tennessee Oncology PLLC, Nashville

37404

Tennessee Oncology, Chattanooga

45242

Oncology Hematology Care, Cincinnati

60425

Ingalls Cancer Research Center, Harvey

64132

Research Medical Center, Kansas City

76104

Center for Cancer and Blood Disorders, Fort Worth

80218

Rocky Mountain Cancer Centers, Denver

Sponsors

Collaborators (1)

Celgene
All Listed Sponsors
collaborator

Celgene

INDUSTRY

lead

SCRI Development Innovations, LLC

OTHER

NCT02317991 - Study of Nab-Paclitaxel and Ramucirumab as Second-line Treatment for Patients With Metastatic Gastroesophageal Cancer | Biotech Hunter | Biotech Hunter